TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc.

TLSI·NASDAQ

$3.18

-0.47%
HealthcareMedical - Devices

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

At a Glance

Live Snapshot
Market Cap$120.55M
EPS-1.8400
P/E Ratio-1.73
Earnings Date08/11/2026

tlsi

Revenue

Last Annual Value

45.15M

3-Year CAGR

54%

5-Year CAGR

%

10-Year CAGR

%

TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. Competitors Analysis of Revenue

TLSI · NASDAQ
CompanyRevenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
45.15M
34.6%40.0%N/A 
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
33.03M
-7.2%-0.5%10.4%
0.00
N/AN/AN/A
77.36M
-1.5%9.6%N/A
HYPR logo
Hyperfine, Inc.
NASDAQ:HYPR
13.56M
7.1%55.4%N/A
71.61M
12.6%16.7%50.8%
33.59M
14.3%7.7%N/A
LNSR logo
LENSAR, Inc.
NASDAQ:LNSR
58.44M
11.5%11.1%N/A
884.00K
-14.9%-39.4%-15.5%
149.16M
27.9%21.9%15.9%
4.90M
2.7%1.9%34.1%
TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. Fair Value Envelope

TLSI · NASDAQ

Our analysis suggests that TLSI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.18, this represents a potential HIDDEN relative to our calculated worth for TriSalus Life Sciences, Inc..

Intrinsic Value
Current Price: $3.18